Skip Navigation


Carcinogenesis Advance Access originally published online on July 20, 2006
Carcinogenesis 2007 28(2):280-288; doi:10.1093/carcin/bgl123
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
28/2/280    most recent
bgl123v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (3)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Michaud-Levesque, J.
Right arrow Articles by Béliveau, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Michaud-Levesque, J.
Right arrow Articles by Béliveau, R.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2006. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

In vivo inhibition of angiogenesis by a soluble form of melanotransferrin

Jonathan Michaud-Levesque, Michel Demeule and Richard Béliveau*

Laboratoire de Médecine Moléculaire, Service d‘Hémato-Oncologie Hôpital Ste-Justine- UQAM, C.P. 8888, Succursale Centre-ville, Université du Québec à Montréal, Montréal, Québec, Canada H3C 3P8

*To whom correspondence should be addressed. Email: oncomol{at}nobel.si.uqam.ca

Melanotransferrin (MTf), the membrane-bound human melanoma antigen p97, binds to plasminogen and stimulates its activation, thus regulating a crucial step involved in angiogenesis. In our study, a truncated soluble form of MTf (sMTf) inhibits, in a dose-dependent manner, the in vitro tubulogenesis of human umbilical vessel endothelial cells (HUVEC) induced by media conditioned with MTf-expressing cells. Following these results, we used the in vivo MatrigelTM plug angiogenesis assay to investigate whether truncated sMTf could inhibit neovascularization in mice. We found that basic fibroblast growth factor (bFGF), vascular endothelial growth factor (VEGF) and MTf-expressing cells strongly stimulate in vivo MatrigelTM neovascularization. However, subcutaneous (s.c.) administration of truncated sMTf inhibits both bFGF- and VEGF- as well as human melanoma SK-Mel-28-induced angiogenesis. This inhibition was dependent on the truncated sMTf concentration and reached maximal inhibition at 40 mg/kg/week. Furthermore, we found that a single s.c. injection of truncated sMTf into nude mice at 5 mg/kg produced a maximal blood concentration of ~40 nM, which is comparable with the level required to inhibit in vitro HUVEC tubulogenesis. Overall, our results strongly suggest that s.c. administration of truncated sMTf may provide a novel therapeutic strategy for the treatment of angiogenesis-related disorders.

Abbreviations: bFGF, basic fibroblast growth factor; CHO, Chinese hamster ovary; EC, endothelial cells; Hb, hemoglobin; HUVEC, human umbilical vessel EC; mAb, monoclonal antibody; MTf, melanotransferrin; R/H, Ringer/HEPES; sMTf, soluble form of MTf; PA, plasminogen activator; s.c, subcutaneous; VEGF, vascular endothelial growth factor

Received May 5, 2006; accepted June 30, 2006.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.